Xellar Biosystems raises over 200 million RMB in Series A funding to build next-generation drug discovery infrastructure

Xellar Biosystems secured over 200 million RMB in Series A funding, with Crystal Clear Technology participating. The funding will advance Xellar's AI and organ-on-a-chip platform for next-generation drug discovery infrastructure. Crystal Clear Technology, an existing investor, collaborates on AI-driven drug screening. Xellar's platform aims to improve drug development efficiency and accuracy by simulating human physiology and disease states. The company is also working with the FDA on its innovative drug development tools program.